2022 Annual Report

Lilly Cares[®] Foundation





In 2022 the Lilly Cares® Foundation (Lilly Cares) provided more than 217,000 patients in the U.S. prescribed Eli Lilly and Company (Lilly) medication at no cost through the Lilly Cares Patient Assistance Program (PAP).

2022 was a milestone year for Lilly Cares as we crossed the 200K patient mark, which is nearly double the number of patients we served annually only five years ago, and a 26 percent increase from 2021. Nearly 167,000, or 77 percent of the patients supported by Lilly Cares in 2022 received medication for diabetes, and 17 percent of Lilly Cares patients are receiving more than one donated Lilly medication. The free medication the foundation provided to the increasing number of qualifying patients in 2022 was valued at \$3.4 billion.

While we continue to see year-over-year growth in the number of patients served by Lilly Cares, we remain fully committed to improving operational efficiency and applicant experience. In 2022, we made enhancements to the Medicare Part D enrollment process by initiating annual re-enrollment for patients in October to ease the year-end rush. We've also made a change to our process so Medicare Part D patients, who enroll for the first time towards the end of the calendar year, can be enrolled through the following calendar year avoiding the need to immediately re-apply to the program.

Our new income verification process, initiated in 2021, has proven to be an effective solution to more efficiently intake

Lilly Cares PAP patients. Since implementation, well over 200,000 applicants benefited from no longer needing to find and submit documentation to provide proof of their income with their initial application. Instead, a third-party consumer reporting agency is able to quickly validate most applicant's household income. This process enhancement has improved consistency and generally accelerated the speed of enrollments.

I am incredibly proud of all we've accomplished in 2022, but there is more work to be done. Staying true to our core value of having patients at the center of all we do, we are planning for more process improvements and operational efficiencies in 2023, focusing on consolidating our pharmacy operations to streamline prescription processing and timely medication delivery. I hope that you find this annual report helpful and informative. Please visit www.lillycares.com for more information about Lilly Cares.


Ima t. Tragesser

Irma E. Tragesser
President, Lilly Cares Foundation






217,000+ TOTAL PATIENTS SERVED



17% of enrolled patients were able to receive multiple medications from Lilly Cares at no cost. More than 8,000 patients in need received at least 3 prescribed medications.

\$3.4+ BILLION IN MEDICATIONS PROVIDED








2022 LILLY CARES IMPACT, CONTINUED

HIGHEST REQUESTED MEDICATIONS



State-level numbers regarding patients served through Lilly Cares in 2022 can be found on lillycares.com/resources under Lilly Cares News and Reports.

MEDICATIONS PROVIDED BY LILLY CARES

Diabetes

BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon (glucagon for injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection

Immune Disorders

Olumiant® (baricitinib); Taltz® (ixekizumab) injection

Cancer

Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Retevmo® (selpercatinib); Verzenio® (abemaciclib)

Women's, Men's and Children's Health

Cialis® (tadalafil); Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection

Mental Health

Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)

Pain

Emgality® (galcanezumab-gnlm) injection; REYVOW® (lasmiditan)

Your program is truly changing our patients' lives. So, thank you again.

-Clinical Pharmacist







Lilly Cares® is a registered trademark of Eli Lilly and Company. All medications listed in this report are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. PP-AP-US-0530 05/2023 © Lilly USA, LLC 2023. All rights reserved.

